Introduction

Tesamorelin is a growth-hormone-releasing hormone analogue that stimulates endogenous growth-hormone signaling and increases IGF-1. Unlike many compounds in the Elev8 research catalog, tesamorelin is also the active ingredient in FDA-approved prescription products for a specific indication. The approved pharmaceutical formulations must not be represented as interchangeable with Elev8 research vials.

Research Areas

Mechanisms

Tesamorelin acts on growth-hormone-releasing hormone receptors, stimulating pulsatile endogenous growth-hormone release with downstream increases in IGF-1.

Human Evidence

Randomized trials involving people with HIV-associated abdominal fat accumulation demonstrated reductions in visceral adipose tissue. Additional research has examined liver fat, metabolic markers, body composition and inflammatory markers.

Preclinical Evidence

Preclinical GHRH-analogue research informed the development pathway, but the compound's evidentiary strength rests on its human trial program.

Limitations

The FDA-approved EGRIFTA formulation has formulation-specific ingredients, strengths, preparation instructions and regulatory approval. Elev8 10 mg and 20 mg research vials are not represented as equivalent, bioequivalent, or interchangeable with EGRIFTA. Trial outcomes were observed in a defined clinical population under medical supervision.

Safety & Regulatory

Approved labeling exists for the pharmaceutical formulation and its specific indication. Elev8 research material is not FDA approved and is offered for laboratory research use only.

Conclusion

Tesamorelin illustrates why formulation matters: strong human evidence exists for an approved product and indication, and that evidence cannot be transferred to research material.